Anti- Rituximab (Anti-Idiotype) Antibody, R&D Systems™

Rituximab

Western Blot 0.5 ug/mL, Flow Cytometry 0.25 ug/10^6 cells, ELISA, Binding Inhibition 2.5 ug/mL

Monoclonal

Supernatant

Multi-species

B lymphocyte antigen CD20, B lymphocyte surface antigen B1, Bp35, CD20, LEU 16, LEU16, Membrane spanning 4 domains subfamily A member 1, MS4A1

IgG

Protein A or G purified from cell culture supernatant

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.

2260A

Western Blot, Flow Cytometry, ELISA

Unconjugated

Rabbit

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS.

Full-length Rituximab

Primary

Reconstitute at 0.5 mg/mL in sterile PBS.

Detects Rituximab in Western blots in direct ELISAs. 100% cross-reactivity with Tositumomab and Ibritumomab (95% or higher sequence identity with Rituximab) and no cross-reactivity with Cetuximab, Trastuzumab, Brentuximab, Gemtuzumab, Adalimumab, Solanezumab, Teprotumumab, and Aducanumab is observed.